Solvonis Therapeutics Raises £1M to Accelerate AI-Driven CNS Drug Discovery for Depression and Stimulant Addiction
Key Insights
Solvonis Therapeutics (search) secured £1.0 million from three major shareholders to accelerate its AI-supported central nervous system (search) drug discovery programme targeting depression and stimulant use disorders.
The funding will enable lead identification and early-stage candidate validation in therapeutic areas with significant unmet needs, including stimulant addiction which currently has no FDA-approved medications.
The company's AI-enabled R&D platform integrates proprietary compound libraries and predictive modelling to drive innovation in neuropsychiatric conditions traditionally marked by low investment and slow progress.
Solvonis Therapeutics (search) plc has raised £1.0 million through a direct subscription from three of its largest shareholders to accelerate its artificial intelligence-supported central nervous system (search) drug discovery programme. The clinical-stage biopharmaceutical company sold 333,333,334 new ordinary shares at 0.3 pence each, representing approximately a 3.5% premium to the previous day's closing price.
The funding will specifically target two therapeutic areas with significant unmet medical needs: major depressive disorder (search) and stimulant use disorder (search). According to Global Market Insights (search), the global antidepressant drug market was valued at approximately £15 billion in 2024, with projections showing a compound annual growth rate of 7.5% through to 2034.
Addressing Critical Treatment Gaps
Stimulant use disorders, including those related to cocaine and amphetamine dependence (search), represent a particularly underserved area in pharmaceutical development. Despite the substantial public health burden these conditions represent, no FDA-approved medications are currently available for treatment, according to U.S. Veterans Affairs Health Services R&D (search) data cited by the company.
"We are pleased to receive this investment from our largest and longest-standing shareholders," said Anthony Tennyson, Chief Executive Officer of Solvonis. "Their continued conviction supports our strategy to lead innovation in addiction and mental health therapeutics, including the acceleration of our proprietary AI-supported discovery platform."
AI-Enabled Discovery Platform
Solvonis' R&D platform integrates proprietary compound libraries, predictive modelling, and rapid translational tools to drive discovery in areas traditionally marked by low investment and slow innovation. The company describes itself as uniquely positioned to address high-burden neuropsychiatric conditions through this AI-enabled, central nervous system (search)-focused approach.
The net proceeds from the subscription will enable the company to accelerate lead identification and early-stage candidate validation across these two core therapeutic indications. In June, Solvonis was granted a US patent for compounds that are part of this programme.
Market Response and Share Structure
Following the announcement, Solvonis shares rose 20% to 0.35 pence in London trading, giving the company a market capitalisation of £20.6 million. The subscription shares are expected to be admitted to trading on the Main Market of the London Stock Exchange on or around 17 July 2025.
After admission, the company's enlarged issued ordinary share capital will comprise 6,242,104,024 ordinary shares. The subscription reflects continued strong support from the company's largest shareholders for its strategic focus on addiction and mental health therapeutics.
Broader Pipeline Context
Beyond this AI-supported discovery programme, Solvonis maintains a clinical-stage pipeline addressing alcohol use disorder (search) and post-traumatic stress disorder (search). The company estimates these conditions affect over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 trials for severe alcohol use disorder in the UK and EU, while SVN-002 is preparing for Phase 2b trials in the US.